股票代码：000915 股票简称：华特达因 公告编号：2023-024 山东华特达因健康股份有限公司 第十届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 山东华特达因健康股份有限公司第十届监事会于 2023 年 8 月 7 日以电子邮件形式发出召开第九次会议的通知，并于 2023 年 8 月 17 日在公司会议室召开会议。会议应参加监事5名，实际参加监事5名。 会议由监事会主席郑波先生主持。会议符合有关法律、法规、规章和 《公司章程》的规定。 （三）备查文件 经与会监事签字并加盖监事会印章的监事会决议。 特此公告 二、监事会会议审议情况 以 5 票同意 0 票弃权 0 票反对的表决结果，审议通过了《公司 2023 年半年度报告》并发表如下审核意见： 经审核，监事会认为董事会编制和审议《公司 2023 年半年度报 告》的程序符合法律法规及深圳证券交易所规定的要求，报告内容真 实、准确、完整地反映了上市公司的实际情况，不存在任何虚假记载、 误导性陈述或者重大遗漏。 山东华特达因健康股份有限公司监事会 2023 年 ...

独立董事关于公司第十届董事会第九次会议 相关内容的独立意见 关于控股股东及其他关联方占用公司资金、 公司对外担保情况的专项说明和独立意见 根据中国证监会《上市公司监管指引第 8 号——上市公司资金往来、 对外担保的监管要求》（证监会公告〔2022〕26 号）、深圳证券交易所《上 市公司自律监管指引第 1 号——主板上市公司规范运作》的规定和要求， 我们对山东华特达因健康股份有限公司（简称"公司"）的控股股东及其 他关联方占用公司资金的情况、公司对外担保情况进行了核查，现发表专 项说明和独立意见如下： 一、2023年1-6月，公司不存在控股股东及其关联方占用上市公司资 金的情况，也没有前期发生延续至本期的情况。 二、截至 2023 年 6 月末公司实际对外担保额为 1,407.51 万元，上述 金额均是公司为控股股东山东华特控股集团有限公司提供的反担保所致， 担保额占公司净资产的 0.52%。担保履行了《公司章程》规定的审批程序， 不存在损害公司和股东利益的情形。 独立董事：吕玉芹 张志元 杜宁 2023 年 8 月 17 日 关于对公司高管薪酬的独立意见 山东华特达因健康股份有限公司第十届董事会第九次会议审议 ...

证券代码：000915 证券简称：华特达因 | 挂，已经比大股东增持 1%的时候低，请问大股东有增持计划 | | --- | | 吗？ | | 答：您好，公司目前没有接到大股东的增持计划。 | | 5.问：公司今年会被纳入医药集采么？除了伊可新外，其 | | 他产品年度业绩目标如何？ | | 答：您好，除伊可新等主要产品外，右旋糖酐铁颗粒及复 | | 方碳酸钙泡腾颗粒也是公司 2023 年重点推广产品。 | | 6.问：请问专注医药主营的具体措施，有没有同行业并购 | | 计划，剥离非医药的进程。 | | 答：您好。公司专注儿童制药及健康领域，对非主业将在 | | 发展的基础上择机退出。如有符合企业发展战略的并购标的， | | 公司不排除通过并购方式实现快速发展。 | | 7.问：公司第一季度销售状况？ | | 答：您好，关于公司 2023 年第一季度经营情况，请您关 | | 注公司 2023 年第一季度报告。 | | 8. 问：关心下一代健康成长是中华人民长治久安的根本 | | 前提，也是中华人民尊老爱幼优良传统，请问：（1）公司未 | | 来如何布局儿童健康成长产业，有哪些前瞻设想，并已经开始 | | 了 ...

证券代码：000915 证券简称：华特达因 公告编号：2023-011 山东华特达因健康股份有限公司 关于举行 2022 年年度报告网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 山东华特达因健康股份有限公司（以下简称"公司"）定于 2023 年 3 月 30 日（周四）16:00-17:00 在全景网举办 2022 年年度报告业 绩说明会，本次业绩说明会将采用网络远程的方式举行，投资者可登 陆全景网"投资者关系互动平台"（https://ir.p5w.net）参与本次 年度业绩说明会。 公司出席本次说明会的人员有：总经理杨杰女士、独立董事吕玉 芹女士、董事会秘书范智胜先生、财务负责人王伟女士。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业 绩说明会提前向投资者公开征集问题，广泛听取投资者的意见和建议。 投资者可于 2023 年 3 月 29 日（ 星 期 三 ） 15 ： 00 前访问 https://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集专题页 面。公司将在 2022 年度业绩说明会上，对投资者 ...

Financial Performance - The company's operating revenue for Q1 2018 was ¥456,490,788.31, representing a 1.82% increase compared to ¥448,311,308.58 in the same period last year[5]. - The net profit attributable to shareholders decreased by 14.56% to ¥73,931,901.38 from ¥86,531,123.69 year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses also fell by 14.84% to ¥73,569,011.25[5]. - Basic and diluted earnings per share decreased by 13.51% to ¥0.32 from ¥0.37[5]. - The weighted average return on equity declined by 1.73 percentage points to 4.79% from 6.52%[5]. Cash Flow and Assets - The net cash flow from operating activities surged by 974.35% to ¥90,939,989.43, compared to ¥8,464,653.19 in the previous year[5]. - Total assets increased by 2.52% to ¥2,844,830,963.72 from ¥2,775,008,183.76 at the end of the previous year[5]. - As of March 31, 2018, the company's prepayments increased by 44.64% to ¥62,781,859 compared to ¥43,406,255.65 at the end of 2017, primarily due to increased marketing expenses by its subsidiary Shandong Dain Ocean Biological Pharmaceutical Co., Ltd.[14]. - Other current assets rose by 72.13% to ¥2,993,396.14, attributed to an increase in unrecoverable input tax and accrued repair costs[14]. - The company's construction in progress increased by 34.26% to ¥163,431,439.99, mainly due to payments made for construction by its subsidiary[14]. Expenses and Financial Management - Sales expenses surged by 72.40% to ¥132,577,654.52, driven by higher marketing costs incurred by its subsidiary[14]. - The company reported a 125.12% rise in financial expenses to ¥1,301,631.11, primarily due to increased cash discounts by its subsidiary[14]. - The company's long-term deferred expenses increased by 30.58% to ¥17,377,443.61, mainly due to office renovation costs incurred by its subsidiary[14]. - The company’s cash paid for investments decreased by 58.51% to ¥66,408,420.54, attributed to reduced purchases of bank wealth management products by its subsidiary[15]. - The company’s cash paid for debt repayment decreased by 47.50% to ¥21,000,000, reflecting a reduction in bank loan repayments[15]. Shareholder Information - The company reported a total of 26,520 common shareholders at the end of the reporting period[10]. - The largest shareholder, Shandong University Industry Group Co., Ltd., holds 20.72% of the shares, amounting to 48,544,340 shares[10]. - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[11]. Other Developments - The company is in the process of transferring property ownership for the purchased "Beijing Dain High-Tech Children's Drug Research Institute Co., Ltd."[16].

Financial Performance - The company's operating revenue for 2017 was ¥1,767,233,195.23, representing a 14.40% increase compared to ¥1,544,725,068.68 in 2016[17] - The net profit attributable to shareholders for 2017 was ¥243,200,947.33, which is a 22.59% increase from ¥198,385,162.89 in 2016[17] - The net profit after deducting non-recurring gains and losses was ¥239,132,177.79, up 22.30% from ¥195,527,172.05 in the previous year[17] - The basic earnings per share for 2017 was ¥1.04, reflecting a 22.35% increase from ¥0.85 in 2016[17] - The total assets at the end of 2017 amounted to ¥2,775,008,183.76, an increase of 11.80% from ¥2,482,210,141.83 at the end of 2016[17] - The net assets attributable to shareholders at the end of 2017 were ¥1,499,444,839.60, which is a 16.78% increase from ¥1,283,989,079.96 in 2016[17] - The net cash flow from operating activities for 2017 was ¥426,108,916.98, a decrease of 14.93% compared to ¥500,913,721.16 in 2016[17] - The weighted average return on equity for 2017 was 17.50%, an increase of 0.88 percentage points from 16.62% in 2016[17] Revenue Breakdown - Revenue from pharmaceutical products reached ¥1,194,563,581.47, accounting for 67.60% of total revenue, with a year-on-year growth of 35.68%[40] - Revenue from environmental protection equipment and engineering decreased by 35.91% to ¥242,090,710.16, down from ¥377,714,009.55 in 2016[40] - Sales revenue from products accounted for 67.60% of total revenue, while engineering installation revenue contributed 13.58% and tuition income made up 9.25%[191] Dividend Distribution - The company plans to distribute a cash dividend of ¥2.50 per 10 shares, based on a total share capital of 234,331,485 shares as of December 31, 2017[5] - The total cash dividend amount for 2017 is 58,582,871.25 CNY, which represents 24.09% of the net profit attributable to ordinary shareholders[83] - In 2016, the company distributed a cash dividend of 1.5 CNY per 10 shares and issued 3 bonus shares per 10 shares[79] Research and Development - Research and development investment amounted to ¥50,761,185.76 in 2017, a decrease of 13.65% compared to ¥58,786,969.22 in 2016, representing 2.87% of operating revenue[52] - The number of R&D personnel increased to 248, up by 5.08% from 236 in the previous year, although the proportion of R&D personnel to total staff slightly decreased[52] - The company has 6 R&D projects currently awaiting review, including oral rehydration salts and various allergy medications[51] Corporate Governance - The company has established a strong governance structure with a mix of experienced professionals and independent directors to oversee operations[152] - The management team is committed to enhancing corporate governance and strategic decision-making processes[153] - The company maintains complete independence from its controlling shareholder in terms of business, personnel, assets, institutions, and finance[172] Market Position and Strategy - The company is focusing on expanding its environmental protection business, particularly in air and water treatment sectors, amidst increasing regulatory pressures[31] - The pharmaceutical industry is expected to benefit from favorable policies regarding children's medication and the "two-child" policy[72] - The company has identified significant growth opportunities in the environmental protection sector due to ongoing large-scale investments and regulatory changes[73] Employee Engagement and Culture - The company’s employee engagement and corporate culture initiatives were strengthened, fostering a positive work environment[37] - The remuneration policy links employee income to the company's economic performance, following principles of "position-based salary" and "performance-based pay"[162] - The company has implemented a training plan to enhance employee skills based on management and business development needs[163] Financial Management - The company reported a significant increase in fixed assets, which rose to CNY 642,612,138.53 from CNY 522,331,176.54, reflecting a growth of about 23%[200] - The total non-current assets amounted to CNY 1,305,130,060.58, up from CNY 1,172,412,577.20, indicating an increase of approximately 11.3%[200] - The company reported a goodwill balance of 28.384 million as of December 31, 2017, with an impairment provision of 2.2506 million, resulting in a net goodwill value of 26.1334 million[188] Shareholder Information - The company’s major shareholder, Shandong Shanda Industrial Group Co., Ltd., holds a 20.72% stake[136] - The top 10 shareholders include Shandong Shanda Industry Group Co., Ltd. with 48,544,340 shares, accounting for a significant portion of the company's equity[138] - The company has a stable shareholder structure with no significant changes reported[145] Internal Controls and Compliance - The company had zero significant deficiencies in financial reporting and internal controls, indicating effective internal control systems[183] - The independent directors attended all board meetings and shareholder meetings, with no objections raised regarding company matters during the reporting period[176][177] - The internal control audit report was disclosed on March 15, 2018, confirming the effectiveness of financial reporting controls[183]

Financial Performance - Operating revenue for the current period reached CNY 481,913,056.26, a 26.18% increase year-on-year[5] - Net profit attributable to shareholders increased by 29.58% to CNY 69,505,393.31 compared to the same period last year[5] - Basic earnings per share rose by 30.43% to CNY 0.30[5] - The net profit attributable to the parent company increased by 35.55% to RMB 216,237,657.04, mainly due to the increase in net profit from pharmaceutical products[17] - Investment income surged by 161.02% to RMB 2,470,849.27, attributed to the returns from bank financial products purchased by the company[15] Assets and Liabilities - Total assets increased by 14.13% to CNY 2,832,852,419.50 compared to the end of the previous year[5] - Net assets attributable to shareholders increased by 14.67% to CNY 1,472,343,478.59 compared to the end of the previous year[5] - Accounts receivable rose by 33.22% to RMB 254,750,798.62, primarily due to an increase in receivables from sales[15] - Other payables rose by 87.96% to RMB 119,267,909.25, primarily due to an increase in unpaid sales expenses[15] - The company’s total liabilities decreased significantly, with accounts payable dropping by 86.34% to RMB 4,752,021.21, due to the payment of matured bank acceptance bills[15] Cash Flow - Cash flow from operating activities decreased by 25.31% to CNY 267,731,595.48 year-to-date[5] - Cash received from investment increased by 85.61% to RMB 278,050,000.00, mainly due to the recovery of bank financial products[17] Shareholder Information - The total number of shareholders at the end of the reporting period was 17,560[10] - The largest shareholder, Shandong University Industry Group Co., Ltd., holds 20.72% of the shares[10] - No repurchase transactions were conducted by the top 10 shareholders during the reporting period[12] Expenses - Sales expenses increased by 45.05% to RMB 338,459,360.27, corresponding to the rise in operating income[15] - The company’s total tax expenses increased by 42.51% to RMB 69,205,727.50, reflecting the growth in total profit for the period[15] - The company’s cash paid for employee compensation increased by 31.04% to RMB 198,017,282.78, due to higher salary payments[17] - The company’s financial expenses decreased by 72.44% to RMB 5,067,706.49, mainly due to a reduction in cash discounts[15] Non-Recurring Items - The company has not reclassified any non-recurring gains and losses as recurring[8]

Financial Performance - The company's operating revenue for the reporting period was ¥865,121,632.25, representing a 20.89% increase compared to ¥715,643,618.14 in the same period last year[18]. - The net profit attributable to shareholders was ¥146,732,263.73, up 38.58% from ¥105,886,296.60 year-on-year[18]. - The net profit after deducting non-recurring gains and losses was ¥146,625,427.19, reflecting a 41.74% increase from ¥103,447,807.01 in the previous year[18]. - The basic earnings per share increased to ¥0.63, a 40.00% rise from ¥0.45 in the same period last year[18]. - The total revenue for the company was ¥862,030,453.56, representing a 22.01% increase compared to the previous year[39]. - Operating profit for the first half of 2017 was CNY 319,543,848.23, representing a 48.83% increase from CNY 214,784,647.61 in the prior year[106]. - The total comprehensive income for the current period is CNY 198,385,162.89, showing a significant increase compared to the previous period[121]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,581,947,943.27, which is a 4.02% increase from ¥2,482,210,141.83 at the end of the previous year[18]. - The total liabilities decreased from RMB 532,894,293.75 to RMB 386,673,553.43 during the reporting period[102]. - The total equity of the company increased from RMB 1,949,315,848.08 to RMB 2,195,274,389.84, reflecting a growth of approximately 12.6%[102]. - The total liabilities at the end of the current period are CNY 792,436,304.56, which is a critical factor for assessing the company's financial leverage[122]. Cash Flow - The net cash flow from operating activities was ¥90,890,957.73, down 46.60% from ¥170,203,608.84 in the same period last year[18]. - The company's cash flow from operating activities decreased by 46.60% to 90.89 million yuan, mainly due to increased tax payments[35]. - The net cash flow from investing activities was -¥209,096,460.63, worsening from -¥182,321,316.02 in the previous period[111]. - The net cash flow from financing activities was -¥69,962,207.88, compared to -¥20,856,374.00 in the previous period[113]. Segment Performance - The pharmaceutical segment generated a revenue of 589 million yuan, with a net profit of 252 million yuan, reflecting growth of 37.54% and 55.02% respectively[31]. - The environmental business reported a revenue of 136 million yuan, down 16.19% year-on-year due to market factors[31]. Shareholder Information - The total number of shares increased from 180,254,989 to 234,331,485 due to a rights distribution plan, which included a cash dividend of 1.50 RMB per 10 shares and a bonus issue of 3 shares[83]. - The largest shareholder, Shandong Shanda Industry Group Co., Ltd., holds 20.72% of the shares, amounting to 48,544,340 shares, with a significant portion pledged[87]. - The company has a total of 14,317 common stock shareholders at the end of the reporting period, indicating a broad shareholder base[87]. Research and Development - The company is focusing on innovation and new product development, particularly in the pediatric medicine sector, enhancing its competitive edge[29]. - The company has established a research center and a children's medicine research institute in Beijing to strengthen new product development[51]. Corporate Governance - The company has not engaged in any major related party transactions during the reporting period[63]. - There are no significant litigation or arbitration matters reported during the period, with a pending case involving a land transfer contract amounting to CNY 31.17 million[60]. - The half-year financial report has not been audited[58]. Environmental and Social Responsibility - The company aims to improve its environmental business sustainability by exploring new business models and enhancing policy and market analysis[51]. - There are no significant environmental protection issues reported, and the company is not classified as a key pollutant discharge unit[80]. Accounting Policies - The company’s financial statements are prepared based on the going concern assumption, in accordance with the relevant accounting standards and regulations[137]. - The company recognizes research and development expenditures in the research phase as current period expenses, while development phase expenditures are recognized as intangible assets if specific criteria are met[183]. - Deferred tax assets and liabilities are recognized based on temporary differences between the book value of certain assets and liabilities and their tax bases[198].

Financial Performance - The company's operating revenue for 2016 was ¥1,544,725,068.68, representing a 25.29% increase compared to ¥1,232,966,348.39 in 2015[17] - The net profit attributable to shareholders for 2016 was ¥198,385,162.89, which is a 30.13% increase from ¥152,456,087.77 in 2015[17] - Basic earnings per share for 2016 were ¥1.10, up 29.41% from ¥0.85 in 2015[17] - The net profit after deducting non-recurring gains and losses was ¥195,527,172.05, reflecting a 37.80% increase from ¥141,896,953.93 in 2015[17] - Total revenue for 2016 reached ¥1,544,725,068.68, a 25.29% increase from ¥1,232,966,348.39 in 2015[35] - The company reported a financial expense reduction from ¥57,915,640.93 to ¥27,536,604.61, a decrease of 52.4%[175] - The total comprehensive income for the period was 180,254,989.00 CNY, with a significant increase compared to the previous period[194] Cash Flow and Assets - The net cash flow from operating activities reached ¥500,913,721.16, marking a significant increase of 72.59% from ¥290,236,595.22 in the previous year[17] - Operating cash inflow totaled CNY 1,859,318,288.01, representing a 34.19% increase compared to the previous year[49] - The company's cash and cash equivalents increased by 3,233.91% to CNY 111,346,084.60, primarily due to the increase in net cash flow from operating activities[50] - The total assets at the end of 2016 amounted to ¥2,482,210,141.83, a 19.28% increase from ¥2,080,909,422.19 at the end of 2015[17] - Cash and cash equivalents increased to CNY 616,189,740.90 from CNY 414,619,669.52, marking a growth of around 48.7%[165] - The company's accounts receivable decreased to CNY 191,232,015.19 from CNY 225,807,850.70, a decline of about 15.3%[165] Investment and R&D - The company authorized a total of 23 intellectual property rights in 2016, indicating a strong focus on innovation[31] - Research and development investment increased by 14.43% year-on-year to CNY 58,786,969.22, accounting for 3.81% of operating revenue[48] - The company signed a significant contract to establish a subsidiary, Beijing Dain High-tech Children's Drug Research Institute, to enhance its R&D capabilities in pediatric medications[41] - R&D efforts led to 23 intellectual property rights granted, including 4 inventions and 11 utility models, indicating a strong focus on innovation[45] Market and Business Operations - The pharmaceutical sector, led by Dain Pharmaceutical, focuses on children's health products, with "Yikexin" being a well-known brand in the market[25] - The environmental protection segment has established a strong market presence in air pollution control and has been recognized for its "Huate" brand products[26] - The overall growth of the pharmaceutical manufacturing industry in China was 9.7% in revenue and 13.9% in profit in 2016[26] - The company is actively exploring new business models and product development to drive future growth[31] Shareholder and Dividend Information - The company plans to distribute a cash dividend of ¥1.50 per 10 shares and issue 3 bonus shares per 10 shares[5] - The total cash dividend for 2016 is projected to be 27,038,248.35 CNY, which represents 13.63% of the net profit attributable to ordinary shareholders[77] Governance and Management - The company maintains independent operations from its controlling shareholder, ensuring no interference in decision-making[147] - The governance structure complies with relevant laws and regulations, enhancing transparency and protecting shareholder rights[146] - The company reported zero major internal control deficiencies during the reporting period, indicating strong internal governance[157] - The company continues to maintain a stable leadership structure with no recent changes in management or board composition[134] Employee and Talent Management - The company employed a total of 2,596 staff, including 1,054 technical personnel and 543 sales personnel[140] - The remuneration policy links employee income to the company's economic performance, ensuring alignment with market salary standards[143] - The company has faced talent risks due to an aging workforce and plans to enhance its talent acquisition and training mechanisms[70] Risks and Challenges - The company recognizes the competitive risks in both its pharmaceutical and environmental businesses, particularly in the children's health sector where it aims to tailor medications for children[69] - The company is focusing on improving operational quality and efficiency while managing risks associated with accounts receivable and cash flow[69]

Financial Performance - The company's revenue for Q1 2017 was ¥448,311,308.58, representing a 35.33% increase compared to ¥331,268,746.34 in the same period last year[4] - Net profit attributable to shareholders for Q1 2017 was ¥86,531,123.69, an increase of 85.70% from ¥46,596,827.33 in the previous year[4] - The basic earnings per share for Q1 2017 was ¥0.48, up 84.62% from ¥0.26 in the same period last year[4] - The company's operating revenue for Q1 2017 was CNY 448,311,308.58, representing a 35.33% increase compared to CNY 331,268,746.34 in Q1 2016, primarily due to growth in pharmaceutical product sales[14] - Net profit attributable to shareholders of the parent company increased by 85.70% to CNY 86,531,123.69 from CNY 46,596,827.33, driven by higher net profits from pharmaceutical products[14] Cash Flow and Expenses - The net cash flow from operating activities decreased significantly by 85.80%, amounting to ¥8,464,653.19 compared to ¥59,627,880.74 in the previous year[4] - The company reported non-operating income of ¥141,018.62 during the reporting period[6] - The company's financial expenses decreased by 93.49% to CNY 578,185.94 from CNY 8,883,811.50, mainly due to a reduction in cash discounts[14] - The company reported a 98.06% increase in income tax expenses, amounting to CNY 28,091,174.88, attributed to an increase in total profit for the period[14] - The company’s management expenses rose by 34.16% to CNY 30,962,783.54, primarily due to increased R&D expenditures[14] - The company’s investment income decreased by 86.70% to CNY 85,461.72 from CNY 642,449.32, mainly due to reduced investment income from bank wealth management products[14] - The company’s cash paid to employees increased by 60.50% to CNY 93,157,645.70, reflecting higher employee compensation[14] - The company’s cash paid for various taxes increased by 107.15% to CNY 102,848,212.27, driven by growth in operating revenue and performance[14] - The company’s cash received from investment decreased by 38.33% to CNY 80,050,000.00, primarily due to a reduction in the maturity of bank wealth management products[14] Assets and Shareholder Information - Total assets at the end of Q1 2017 were ¥2,494,254,925.66, a slight increase of 0.49% from ¥2,482,210,141.83 at the end of the previous year[4] - Net assets attributable to shareholders increased by 6.70% to ¥1,370,064,382.78 from ¥1,283,989,079.96 at the end of the previous year[4] - The weighted average return on equity rose to 6.52%, an increase of 2.38 percentage points from 4.14% in the previous year[4] - The total number of ordinary shareholders at the end of the reporting period was 14,818[8] - The largest shareholder, Shandong University Industry Group Co., Ltd., holds 20.72% of the shares, totaling 37,341,800 shares[8] Regulatory and Certification - The company’s subsidiary, Shandong Dain Marine Biological Pharmaceutical Co., Ltd., received a GMP certificate from the Australian Therapeutic Goods Administration during the reporting period[15]